[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IN2014CN03892A - - Google Patents

Download PDF

Info

Publication number
IN2014CN03892A
IN2014CN03892A IN3892CHN2014A IN2014CN03892A IN 2014CN03892 A IN2014CN03892 A IN 2014CN03892A IN 3892CHN2014 A IN3892CHN2014 A IN 3892CHN2014A IN 2014CN03892 A IN2014CN03892 A IN 2014CN03892A
Authority
IN
India
Prior art keywords
genetically modified
animals
making
methods
same
Prior art date
Application number
Inventor
Lynn Macdonald
Andrew J Murphy
Naxin Tu
Cagan Gurer
Vera Voronina
Sean Stevens
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IN2014CN03892A publication Critical patent/IN2014CN03892A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention provides genetically modified non human animals that express a humanized MHC II protein (humanized MHC II a and ß polypeptides) as well as embryos cells and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.
IN3892CHN2014 2011-10-28 2012-10-26 IN2014CN03892A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161552584P 2011-10-28 2011-10-28
PCT/US2012/062029 WO2013063340A1 (en) 2011-10-28 2012-10-26 Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules

Publications (1)

Publication Number Publication Date
IN2014CN03892A true IN2014CN03892A (en) 2015-10-16

Family

ID=47430036

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3892CHN2014 IN2014CN03892A (en) 2011-10-28 2012-10-26

Country Status (25)

Country Link
US (7) US8847005B2 (en)
EP (4) EP4052572A1 (en)
JP (2) JP6285361B2 (en)
KR (2) KR101926442B1 (en)
CN (3) CN104039133B (en)
AU (4) AU2012327205B2 (en)
BR (1) BR112014009941B1 (en)
CA (1) CA2852962C (en)
CY (2) CY1119283T1 (en)
DK (3) DK2770822T3 (en)
ES (3) ES2640241T3 (en)
HK (2) HK1196999A1 (en)
HR (3) HRP20220616T1 (en)
HU (2) HUE048511T2 (en)
IL (3) IL231895B (en)
IN (1) IN2014CN03892A (en)
LT (3) LT3272214T (en)
MX (1) MX355726B (en)
PL (3) PL3272214T3 (en)
PT (3) PT3590332T (en)
RS (3) RS56330B1 (en)
RU (1) RU2660564C2 (en)
SG (3) SG10201510056SA (en)
SI (3) SI2770822T1 (en)
WO (1) WO2013063340A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065730A3 (en) 2006-04-26 2012-09-19 L-3 Communications Security and Detection Systems, Inc. Multi-source surveillance systems
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
MY172726A (en) 2011-10-28 2019-12-11 Regeneron Pharma Humanized il-6 and il-6 receptor
HUE048511T2 (en) 2011-10-28 2020-07-28 Regeneron Pharma Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules
PT2958938T (en) 2013-02-20 2019-07-23 Regeneron Pharma Mice expressing humanized t-cell co-receptors
KR102211267B1 (en) 2013-02-22 2021-02-04 리제너론 파아마슈티컬스, 인크. Mice expressing humanized major histocompatibility complex
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
KR102309653B1 (en) 2013-03-11 2021-10-08 리제너론 파아마슈티컬스, 인크. Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
PT3175706T (en) 2013-09-23 2019-02-11 Regeneron Pharma Non-human animals having a humanized signal-regulatory protein gene
EP2908626B1 (en) * 2013-10-15 2016-12-07 Regeneron Pharmaceuticals, Inc. Humanized il-15 animals
SG10201900003WA (en) 2013-11-19 2019-02-27 Regeneron Pharma Non-human animals having a humanized b-cell activating factor gene
HUE051088T2 (en) 2014-04-08 2021-03-01 Regeneron Pharma Non-human animals having humanized fc-gamma receptors
NO2785538T3 (en) 2014-05-07 2018-08-04
HUE048677T2 (en) 2014-06-19 2020-07-28 Regeneron Pharma Non-human animals having a humanized programmed cell death 1 gene
SG11201701040XA (en) 2014-09-19 2017-03-30 Regeneron Pharma Chimeric antigen receptors
RS61080B1 (en) 2014-11-24 2020-12-31 Regeneron Pharma Non-human animals expressing humanized cd3 complex
SI3850946T1 (en) 2014-12-05 2024-02-29 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 47 gene
RS65664B1 (en) 2014-12-09 2024-07-31 Regeneron Pharma Non-human animals having a humanized cluster of differentiation 274 gene
CA3223798A1 (en) 2015-04-06 2016-10-13 Regeneron Pharmaceuticals, Inc. Humanized t cell mediated immune responses in non-human animals
WO2017087780A1 (en) 2015-11-20 2017-05-26 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized lymphocyte-activation gene 3
AU2017213627B2 (en) * 2016-02-04 2022-05-19 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered ANGPTL8 gene
RU2749715C2 (en) 2016-02-29 2021-06-16 Регенерон Фармасьютикалз, Инк. Rodents characterized by the humanized tmprss gene
EP4218408A1 (en) 2016-06-03 2023-08-02 Regeneron Pharmaceuticals, Inc. Rodents expressing exogenous terminal deoxynucleotidyltransferase
JP7361031B2 (en) 2017-11-30 2023-10-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Non-human animals containing a humanized TRKB locus
CN112040769B (en) 2018-03-24 2023-05-16 瑞泽恩制药公司 Genetically modified non-human animals, methods of manufacture and use for producing therapeutic antibodies against peptide-MHC complexes
CN116420679A (en) 2018-03-26 2023-07-14 瑞泽恩制药公司 Humanized rodents for testing therapeutic agents
LT3823443T (en) 2018-07-16 2024-08-12 Regeneron Pharmaceuticals, Inc. Rodent models of ditra disease and uses thereof
AU2020370254A1 (en) * 2019-10-22 2022-04-14 The Trustees Of Columbia University In The City Of New York Transgenic swine, methods of making and uses thereof, and methods of making human immune system mice
IL293330A (en) 2019-12-02 2022-07-01 Regeneron Pharma Peptide-mhc ii protein constructs and uses thereof
WO2022212582A1 (en) 2021-03-31 2022-10-06 Regeneron Pharmaceuticals, Inc. Genetically modified mice comprising humanized cellular immune system components with improved diversity of tcrβ repertoire
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof
US20240099279A1 (en) 2022-09-22 2024-03-28 Regeneron Pharmaceuticals, Inc. Genetically modified mice expressing components of human cellular immune system
WO2024159071A1 (en) 2023-01-27 2024-08-02 Regeneron Pharmaceuticals, Inc. Modified rhabdovirus glycoproteins and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
WO1991001140A1 (en) 1989-07-25 1991-02-07 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5574205A (en) 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9100481D0 (en) 1991-01-10 1991-02-20 Inst Nat Sante Rech Med Genetically engineered mice
WO1993005817A1 (en) 1991-09-19 1993-04-01 President And Fellows Of Harvard College Transgenic mhc class i and class ii antigen-deficient mammals
EP0663952A4 (en) 1992-09-11 1997-06-11 Univ California Transgenic non-human animals having targeted lymphocyte transduction genes.
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
GB9315303D0 (en) 1993-07-23 1993-09-08 Zeneca Ltd Polypeptide
US5965787A (en) 1995-08-31 1999-10-12 Mayo Foundation For Medical Education And Research HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis
US6002066A (en) 1996-01-16 1999-12-14 Ortho Pharmaceutical Corp. H2-M modified transgenic mice
CA2246333A1 (en) 1996-03-05 1997-09-12 The Scripps Research Institute Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens
WO1998024893A2 (en) 1996-12-03 1998-06-11 Abgenix, Inc. TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM
PT1017721E (en) 1997-09-16 2009-05-07 Univ Oregon Health & Science Recombinant mhc molecules useful for manipulation of antigen-specific t-cells
US6372955B1 (en) 1998-02-17 2002-04-16 Ortho Mcneil Pharmaceutical, Inc. Methods for Producing B cells and antibodies from H2-O modified transgenic mice
KR20010042329A (en) * 1998-03-30 2001-05-25 와일러 제임스 에프. Corticotropin releasing factor receptor 1-deficient mice
AU1023401A (en) 1999-10-12 2001-04-23 Institut Pasteur Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice
US7067308B1 (en) * 2000-03-28 2006-06-27 Bioagri Corporation Vector for genetically modifying non-human animals
US20030124524A1 (en) 2000-06-23 2003-07-03 Kenneth Kornman Screening assays for identifying modulators of the inflammatory or immune response
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2002047474A1 (en) 2000-12-13 2002-06-20 Sumitomo Pharmaceuticals Company, Limited Transgenic animal expressing hla-a24 and utilization thereof
DK1409646T3 (en) 2000-12-19 2012-08-06 Altor Bioscience Corp Transgenic animals comprising a humanized immune system
FR2827302B1 (en) 2001-07-13 2003-10-10 Genoway TRANSGENIC CELL AND ANIMAL MODELING HUMAN ANTIGENIC PRESENTATION AND USES THEREOF
US20040072262A1 (en) 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
US7663017B2 (en) 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
DE10347710B4 (en) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Recombinant vaccines and their use
JP4857450B2 (en) 2004-03-09 2012-01-18 財団法人名古屋産業科学研究所 Transgenic non-human mammal that reproduces the pathology of human rheumatoid arthritis
PT1802193E (en) 2004-10-19 2014-06-23 Regeneron Pharma Method for generating a mouse homozygous for a genetic modification
EP1878798A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
HU0700534D0 (en) 2006-11-24 2007-10-29 Mezoegazdasagi Biotechnologiai Transgenic animal with enhanced immune response and method for the preparation thereof
RU2448979C2 (en) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Human antibodies to delta-like human ligand-4
US20090271884A1 (en) 2008-03-07 2009-10-29 Regeneron Pharmaceuticals, Inc. ES Cell-Derived Mice From Diploid Host Embryo Injection
US20090328240A1 (en) 2008-06-24 2009-12-31 Sing George L Genetically modified mice as predictors of immune response
DK2564695T3 (en) 2009-07-08 2015-05-26 Kymab Ltd Animal models and therapeutic molecules
CN101695587B (en) * 2009-10-21 2012-08-29 上海中山医疗科技发展公司 Method for preparing endothelial progenitor cell capturing bracket for gene modification and regulation
BR112013000985A2 (en) 2010-07-15 2017-09-05 Technion Res & Dev Foundation ISOLATED HIGH AFFINITY ENTITIES WITH T-CELL RECEPTOR SPECIFICITY WITH RESPECT TO NATIVE MHC CLASS II COMPLEXES AND AUTOANTIGENIC GLUTAMIC ACID DECARBOXYLASE (GAD) PEPTIDES
WO2012039779A1 (en) 2010-09-24 2012-03-29 The United States Of America As Represented By The Secretary Of The Navy Humanized transgenic mouse model
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
HUE048511T2 (en) 2011-10-28 2020-07-28 Regeneron Pharma Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules
PT2958938T (en) 2013-02-20 2019-07-23 Regeneron Pharma Mice expressing humanized t-cell co-receptors
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
KR102211267B1 (en) 2013-02-22 2021-02-04 리제너론 파아마슈티컬스, 인크. Mice expressing humanized major histocompatibility complex
KR102309653B1 (en) 2013-03-11 2021-10-08 리제너론 파아마슈티컬스, 인크. Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
CA3223798A1 (en) 2015-04-06 2016-10-13 Regeneron Pharmaceuticals, Inc. Humanized t cell mediated immune responses in non-human animals

Also Published As

Publication number Publication date
EP4052572A1 (en) 2022-09-07
CN108401986A (en) 2018-08-17
RU2660564C2 (en) 2018-07-06
NZ623146A (en) 2016-06-24
AU2012327205A1 (en) 2013-05-23
LT3590332T (en) 2022-08-10
US10986822B2 (en) 2021-04-27
PT3590332T (en) 2022-05-27
HRP20220616T1 (en) 2022-06-24
US9585373B2 (en) 2017-03-07
AU2016202317B2 (en) 2017-11-30
BR112014009941B1 (en) 2022-11-29
SI2770822T1 (en) 2017-10-30
HRP20200305T1 (en) 2020-06-12
EP3272214A1 (en) 2018-01-24
JP2014532411A (en) 2014-12-08
US20130111616A1 (en) 2013-05-02
EP2770822B1 (en) 2017-06-14
US8847005B2 (en) 2014-09-30
KR20140089558A (en) 2014-07-15
CY1119283T1 (en) 2018-02-14
RU2018115251A (en) 2019-03-04
US20240365761A1 (en) 2024-11-07
HUE048511T2 (en) 2020-07-28
LT3272214T (en) 2020-03-10
HUE034374T2 (en) 2018-02-28
PL3272214T3 (en) 2020-06-29
IL231895B (en) 2018-07-31
PT2770822T (en) 2017-09-18
RU2014116577A (en) 2015-12-10
KR20180132970A (en) 2018-12-12
JP6652529B2 (en) 2020-02-26
CN108401986B (en) 2021-09-21
EP3272214B1 (en) 2019-11-27
CA2852962A1 (en) 2013-05-02
US20190239496A1 (en) 2019-08-08
LT2770822T (en) 2017-10-10
SG10201909638UA (en) 2019-11-28
KR101926442B1 (en) 2018-12-12
US11219195B2 (en) 2022-01-11
SI3590332T1 (en) 2022-07-29
AU2016202317A1 (en) 2016-05-05
JP6285361B2 (en) 2018-02-28
HRP20171327T1 (en) 2017-11-03
AU2018201402A1 (en) 2018-03-15
ES2774488T3 (en) 2020-07-21
DK2770822T3 (en) 2017-09-25
EP2770822B9 (en) 2019-12-11
PL3590332T3 (en) 2022-06-13
AU2021200438B2 (en) 2023-11-02
AU2021200438A1 (en) 2021-02-25
US20150040253A1 (en) 2015-02-05
HK1250131A1 (en) 2018-11-30
DK3272214T3 (en) 2020-03-02
ES2914374T3 (en) 2022-06-10
PL2770822T3 (en) 2017-11-30
RS56330B1 (en) 2017-12-29
NZ717130A (en) 2018-07-27
IL231895A0 (en) 2014-05-28
IL260209B (en) 2019-12-31
AU2018201402B2 (en) 2020-10-22
US20190239497A1 (en) 2019-08-08
US10219493B2 (en) 2019-03-05
CY1122700T1 (en) 2021-03-12
JP2018019700A (en) 2018-02-08
EP2770822A1 (en) 2014-09-03
US20170135329A1 (en) 2017-05-18
US20210195878A1 (en) 2021-07-01
CN104039133A (en) 2014-09-10
AU2018201402C1 (en) 2021-05-06
KR102113108B1 (en) 2020-05-20
PT3272214T (en) 2020-03-04
HK1196999A1 (en) 2015-01-02
MX2014004896A (en) 2014-09-12
RS59997B1 (en) 2020-04-30
SG10201510056SA (en) 2016-01-28
BR112014009941A2 (en) 2020-12-22
CN108707608A (en) 2018-10-26
WO2013063340A1 (en) 2013-05-02
EP3590332B1 (en) 2022-02-23
RU2018115251A3 (en) 2021-09-07
MX355726B (en) 2018-04-27
SI3272214T1 (en) 2020-04-30
AU2012327205B2 (en) 2016-01-14
SG11201400938UA (en) 2014-04-28
CA2852962C (en) 2022-05-03
CN104039133B (en) 2018-05-04
DK3590332T3 (en) 2022-05-23
IL243565A (en) 2017-10-31
ES2640241T3 (en) 2017-11-02
RS63220B1 (en) 2022-06-30
EP3590332A1 (en) 2020-01-08
IL260209A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
IN2014CN03892A (en)
MY178723A (en) Genetically modified major histocompatibility complex mice
CY1121223T1 (en) Mice EXPRESSING A HUMANIZED MAJOR COMPLIANCE COMPLEX
AU2013312359A8 (en) Genetically modified non-human animals and methods of use thereof
EP4249507A3 (en) Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
MX2017006802A (en) Non-human animals expressing humanized cd3 complex.
MX2016003636A (en) Non-human animals having a humanized signal-regulatory protein gene.
CL2016003096A1 (en) Methods for harvesting mammalian cell cultures
IN2014MN01879A (en)
MX346500B (en) Methods and compositions for neural disease immunotherapy.
GT201300306A (en) ANTI-ANGPTL3 ANTIBODIES AND USES OF THE SAME
EA201592269A1 (en) METHODS AND COMPOSITIONS FOR REDUCING IMMUNOSUPRESSION BY TUMOR CELLS
MX2020007021A (en) Treatment of cancer using humanized anti-cd19 chimeric antigen receptor.
MX2016008076A (en) Human mesothelin chimeric antigen receptors and uses thereof.
WO2014130671A8 (en) Mice expressing humanized t-cell co-receptors
EA201290567A1 (en) PREPARATION OF HETEROLOGICAL POLYPEPTIDES IN MICROWATEREDES, EXTRA-CELLED MICROWAVE-ALONG CALVES, COMPOSITIONS AND METHODS OF THEIR RECEIVING AND APPLICATION
MX2017008817A (en) Compositions and methods for protein glycosylation.
MY160590A (en) Cd127 binding proteins
TN2012000511A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
IN2014DN11201A (en)
EP2531207A4 (en) Methods and compositions for cancer immunotherapy using flagellin-tumor associated antigen fusion protein expressing tumor cells
DK201300530A (en) Vaccine relating to Pancreas disease in fish
EP2719764A4 (en) Expression vector for animal cells including csp-b 5'-sar factor and method for producing recombinant proteins using same
EP3496530A4 (en) Methods and compositions relating to improved human red blood cell survival in genetically modified immunodeficient non-human animals
MX2021000586A (en) Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules.